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Loss of adipose tissue in cancer cachexia in mice bearing the MAC16 tumour arises from an increased lipid mobilisation through
increased expression of zinc-a2-glycoprotein (ZAG) in white (WAT) and brown (BAT) adipose tissue. Glucocorticoids have been
suggested to increase ZAG expression, and this study examines their role in cachexia and the mechanisms involved. In mice bearing
the MAC16 tumour, serum cortisol concentrations increased in parallel with weight loss, and the glucocorticoid receptor antagonist
RU38486 (25mgkg
 1) attenuated both the loss of body weight and ZAG expression in WAT. Dexamethasone (66mgkg
 1)
administration to normal mice produced a six-fold increase in ZAG expression in both WAT and BAT, which was also attenuated by
RU38486. In vitro studies using 3T3-L1 adipocytes showed dexamethasone (1.68mM) to stimulate lipolysis and increase ZAG
expression, and both were attenuated by RU38486 (10mM), anti-ZAG antibody (1mgml
 1), and the b3-adrenoreceptor (b3-AR)
antagonist SR59230A (10mM). Zinc-a2-glycoprotein also increased its own expression and this was attenuated by SR59230A,
suggesting that it was mediated through the b3-AR. This suggests that glucocorticoids stimulate lipolysis through an increase in ZAG
expression, and that they are responsible for the increase in ZAG expression seen in adipose tissue of cachectic mice.
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Cancer cachexia is characterised by progressive loss of adipose
tissue, which can result in the depletion of 85% of the adipose
tissue mass, when the weight loss reaches 30% (Fearon, 1992). This
loss of fat seems to arise from an increased lipolysis, since both
glycerol and fatty acid turnover has been shown to be elevated by
25%, and is similar to the rate observed in patients with severe
burns (Legaspi et al, 1987). A potential mediator of this increased
lipolysis is a lipid-mobilising factor (LMF), which has been isolated
both from a cachexia-inducing murine adenocarcinoma (MAC16),
and from the urine of patients with cancer cachexia, and has been
shown to be identical with the plasma protein zinc-a2-glycoprotein
(ZAG) (Todorov et al, 1998). Both LMF and ZAG induce lipolysis
directly in isolated adipocytes by a cyclic AMP-mediated process
(Hirai et al, 1998) and this is initiated through binding to a b3-
adrenoreceptor (AR) (Russell et al, 2002). Although it was
originally thought that LMF/ZAG was produced by certain
tumours and circulated to adipose tissue, recent results (Bing
et al, 2004) have shown that ZAG is a natural adipocyte factor
found in both white (WAT) and brown (BAT) adipose tissue.
During weight loss in mice bearing the MAC16 tumour, both ZAG
mRNA and protein increased with increasing weight loss, with a
10-fold increase in ZAG mRNA and protein in WAT, and a 20-fold
increase in ZAG protein expression in BAT, at a weight loss of
24%. Dexamethasone markedly increased levels of ZAG mRNA in
3T3L1 adipocytes, as has previously been reported in human
breast cancer cells (Lopez-Boado et al, 1994). Expression was also
increased by the selective b3-AR agonist BRL 37344, suggesting
that the sympathetic system may also play a role in the regulation
of ZAG expression.
Fasting levels of serum cortisol have been shown to be
significantly higher in weight-losing patients with stage IV breast
cancer than those who have not lost weight (Knapp et al, 1991).
This suggests that changes in serum cortisol may be responsible
for the changes in ZAG expression in WAT and BAT during the
development of cachexia. The 50-flanking region of the human
ZAG gene contains a TATA box, a CAT box, an octamer sequence,
and three possible Sp1-binding sites, which may be involved in
transcriptional regulation of this protein (Ueyama et al, 1993).
Glucocorticoids have been shown to increase ubiquitin expression
in muscle cells through Sp1-binding sites in DNA (Marinovic et al,
2002), and this may indicate a mechanism for the increased ZAG
gene expression.
This study investigates the role of glucocorticoids in ZAG
expression in WAT and BAT during the development of cachexia
and investigates the mechanisms involved.
MATERIALS AND METHODS
Animals
Pure strain NMRI mice were bred in our own colony and fed
economy rodent breeder diet (Special Diet Services, Essex, UK)
and water ad libitum until they reached a minimum weight of 20g.
Animals were implanted s.c. in the flank with fragments of the
MAC16 tumour by means of a trochar, selecting from donor
animals with maximal weight loss (Bibby et al, 1987). All animal
experiments followed a strict protocol, approved by the British
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sHome Office, and the ethical guidelines that were followed met the
standards required by the UKCCR guidelines (Workman et al,
1998) and involved terminating the animals when the weight loss
reached 25–30% of the starting weight or the tumour volume
reached 1cm
3. Weight loss was evident 10–12 days after tumour
transplantation at which time the tumour was just palpable and it
took another 3–5 days to reach 25% weight loss. Blood was
removed from animals with various extents of weight loss by
cardiac puncture under terminal anaesthesia for serum cortisol
determination. To establish a time profile for plasma cortisol
levels, blood was removed by tail bleed, as indicated in the legend
to Figure 1. Animals with established weight loss (5%) were
randomised to receive RU38486 (25mgkg
 1) daily i.p. in PBS as
previously reported (Cheesman and Reilly, 1998), while control
animals received PBS alone. Body weight was measured daily and
recorded as the change in body weight from the start of the
experiment. Tumour volumes were measured daily by means of
callipers, and were recorded as a percentage of the starting tumour
volume. Non-tumour-bearing mice were administered dexametha-
sone (66mgkg
 1) i.p., while control mice received PBS for 24h, as
reported previously (Jacoby et al, 2001). At the end of the
experiment, the animals were humanely killed, and the epididymal
WAT and BAT were removed for Western blot analysis.
Materials
Foetal calf serum (FCS) and Dulbecco’s modified Eagle’s medium
(DMEM) were purchased from InVitrogen (Paisley, Scotland). The
Cortisol ELISA kit was purchased from Autogen Bioclear UK Ltd
(Wiltshire, UK), and assays were performed according to the
manufacturer’s instructions. A standard curve was produced using
murine cortisol. Mouse monoclonal anti-human ZAG antibody
with crossreactivity with mouse ZAG was purchased from Santa
Cruz (California, USA), while rabbit polyclonal antisera to mouse
actin was from Sigma Aldridge (Dorset, UK). Peroxidase-
conjugated rabbit anti-mouse antibody was purchased from Dako
Ltd (Cambridge, UK). Hybondt nitrocellulose membranes and
enhanced chemiluminescence (ECL) were from American Bios-
ciences (Bucks, UK). Human ZAG was supplied by Bayer
Corporation and was purified from Cohn Fraction V effluence
derived from large pools of human plasma as described (Russell
et al, 2004).
Cell culture
3T3-L1 preadipocytes were grown to confluence in DMEM
containing 10% FCS, 1% penicillin/streptomycin, and 1% gluta-
mine in 10% CO2 in air at 371C. At 2 days after the cells reached
confluence, differentiation was initiated by addition of growth
medium containing 0.5mM 3-isobutyl-1-methyl-xanthine, 0.25mM
dexamethasone, and 1mgml
 1 insulin, as described (Frost and
Lane, 1985), with medium changed every 2 days. This was followed
by a further two days in growth medium containing insulin
(1mgml
 1), and growth medium was then changed daily. Cells
were used experimentally between days 8 and 12, at which time
95% of the cells express the adipocyte phenotype as determined by
staining with Oil Red O. For experiments where the media was
sampled, the last media change employed DMEM without phenol
red. The details of the individual experiments are given in the
figure legends. The concentrations of agonists and antagonists
employed were based on previous data: isoprenaline (10mM), ZAG
and LMF (0.57mM), anti-mouse ZAG antibody (1mgml
 1) (Russell
et al, 2004), and RU38486 (10mM) (Mulholland et al, 2004).
Western blotting
Samples of adipose tissue and 3T3-L1 adipocytes were homo-
genised in 0.25 M sucrose, 1mM HEPES, pH 7.0, and 0.2 M EDTA.
Samples of cytosolic protein (10mg), prepared by centrifugation of
the homogenate at 4500r.p.m. for 10min, or neat tissue culture
medium, were resolved on 12% SDS–PAGE. Proteins were then
transferred to nitrocellulose membranes (Hybondt), which had
been blocked with 5% Marvel in Tris-buffered saline, pH 7.5, at
41C overnight. Both primary and secondary antibodies were used
at a dilution of 1 in 1000. Incubation with the primary antibody
was carried out overnight at 41C, and, following four 15-min
washes with 0.1% Tween in PBS, incubation with the secondary
antibody was performed for 1h at room temperature. Develop-
ment was by ECL. Blots were subjected to densitometric analysis
using ‘Phoretix ID Advanced’ software. Equal loading was
confirmed by Ponceau S staining of the membranes and actin
blotting, which was performed on the same samples at the same
time as ZAG.
Statistical analysis
Results are expressed as mean7s.e.m. Differences were deter-
mined by one-way ANOVA, followed by Tukey–Kramer multiple
comparison test. P-values less than 0.05 were considered to be
significant.
RESULTS
The effect of weight loss in mice bearing the MAC16 tumour on
serum cortisol levels over the course of the development of
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Figure 1 (A) Plasma cortisol concentrations in mice bearing the MAC16
tumour with varying extents of weight loss. Blood was removed from
animals by cardiac puncture under terminal anaesthia as described in
Materials and Methods. Number of animals used for each point, n¼3. The
data fit to a straight line relationship (r
2¼0.95). (B) Plasma cortisol
concentrations in tail bleed samples from MAC16 tumour-bearing mice
with time after day 11 after transplantation when weight loss occurred (day
1 in the figure). Weight loss occurred at day 2. n¼3. Differences from no
weight loss are indicated as c, Po0.001.
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scachexia is shown in Figure 1. Serum cortisol concentrations
increased in parallel with the weight loss (Figure 1A) and were
elevated within 1 day of weight loss (Figure 1B), suggesting that it
could be responsible for the increased ZAG expression seen in
adipose tissue of cachectic mice (Bing et al, 2004). To investigate
this possibility, mice bearing the MAC16 tumour and with an
average weight loss of 5% were treated with the glucocorticoid
receptor antagonist RU38486 (25mgkg
 1) and the effect on loss of
body weight and tumour volume was determined (Figure 2).
Treatment with RU38486 completely attenuated loss of body
weight in mice bearing the MAC16 tumour (Figure 2A), while
having no effect on tumour volume (Figure 2B). Western blot
analysis showed that ZAG expression in WAT was upregulated in
mice bearing the MAC16 tumour (Figure 3) and was down-
regulated by 50% (Po0.001) in animals treated with RU38486. To
confirm that circulating glucocorticoids could be responsible for
the increased ZAG expression in mice bearing the MAC16 tumour,
normal mice were administered dexamethasone (66mgkg
 1)b y
i.p. injection, twice at 12-h intervals, and killed at 24h. Western
blotting showed about a two-fold increase in ZAG expression in
both WAT and BAT (Po0.001) (Figure 3C and E), and the effect
was completely attenuated by the glucocorticoid receptor antago-
nist RU38486 (Po0.001 from dexamethasone alone) (Figure 3E),
confirming that it was mediated through the glucocorticoid
receptor.
To investigate the mechanism of the regulation of ZAG
expression by glucocorticoids, further experiments were carried
out in vitro using 3T3-L1 adipocytes. The effect of various
treatments on glycerol release over a 24-h period is shown in
Figure 4. Dexamethasone (1.68mM) stimulated lipolysis to the same
extent as ZAG and LMF (0.57mM), and these values were similar to
those of the positive control (isoprenaline; 10mM). The lipolytic
activity of dexamethasone was attenuated by RU38486 (10mM),
confirming that it was working through the glucocorticoid
receptor. In addition, lipolytic activity was blocked by anti-ZAG
monoclonal antibody (1mgml
 1), suggesting that the action of
dexamethasone on lipolysis was mediated through the induction of
ZAG expression. The selective b3-AR receptor antagonist (Nisoli
et al, 1996) SR59230A (10mM) also completely attenuated the
action of dexamethasone, suggesting that the ZAG produced
moved into the medium and acted extracellularly though b3-AR.
To confirm this hypothesis, ZAG expression in 3T3-L1
adipocytes and media in response to dexamethasone and various
antagonists was determined by Western blotting. As expected from
in vivo data (Figure 3), dexamethasone stimulated a three-fold
increase in ZAG expression in both cells and medium (Figure 5)
(Po0.001 from PBS), and this was attenuated by RU38486
(Po0.001 from dexamethasone). Interestingly, ZAG expression
was also completely downregulated (Po0.001) when dexametha-
sone was combined with SR59230A, suggesting a role for a b3-AR
in the induction of ZAG expression (Figure 6). Anti-ZAG
antiserum also attenuated dexamethasone-induced ZAG expres-
sion (Po0.001), suggesting that ZAG itself may be involved in the
increased gene transcription. This conclusion was substantiated
from studies with ZAG (Figure 7). Zinc-a2-glycoprotein induced
increased expression of ZAG in both 3T3-L1 adipocytes and in
−3.0
−2.5
−2.0
−1.5
−1.0
−0.5
0.0
0.5 123
Time (days)
0
50
100
150
200
250
1234
Time (days)
T
u
m
o
u
r
 
v
o
l
u
m
e
 
 
(
%
 
o
f
 
s
t
a
r
t
i
n
g
 
v
o
l
u
m
e
)
 
c
w
t
 
∆
 
(
g
)
A
B
Figure 2 Effect of RU38486 (25mgkg
 1 i.p. daily) (~) on changes in
body weight (A) and tumour volume (B) in mice bearing the MAC16
tumour. Differences from PBS control (’) are indicated as c, Po0.001.
Number of animals in each group, n¼6. Day 1 is 11 days after
transplantation when the mice start to lose weight.
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Figure 3 (A) Western blot of ZAG expression in WAT of mice bearing
the MAC16 tumour treated with PBS (lanes 1–2) or RU38486
(25mgkg
 1) (lanes 3–4) and in non-tumour-bearing mice treated with
either PBS (lanes 5–6) or RU38486 (25mgkg
 1 i.p. daily for 4 days) (lanes
7–8). The experiment was initiated 11 days after tumour transplantation
when the average weight loss was 5%. (B) Actin loading control for the
blot shown in (A). (C) Western blot of ZAG expression in epididymal
WAT (lanes 1–6) and BAT (lanes 7–12) of non-tumour-bearing NMRI
mice 24h after administration of PBS (lanes 1–3 and 7–9) or
dexamethasone (66mgkg
 1 i.p. daily) (lanes 4–6 and 10–12). n¼6. (D)
Actin loading control for the blot shown in (A). (E) Western blot of ZAG
expression in WAT of NMRI mice treated with PBS (lanes 1–2),
dexamethasone (lanes 3–4), dexamethasoneþRU38486 (25mgkg
 1)
(lanes 5–6) or RU38486 (25mgkg
 1) (lanes 7–8). n¼6. (F) Actin loading
control for the blot shown in (E).
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smedium, and this was attenuated by pretreatment (2h prior to
ZAG) with anti-ZAG antibody (Figure 7A and C). Zinc-a2-
glycoprotein expression was also attenuated by SR59230A
(Figure 8) (Po0.001), suggesting that induction of ZAG is
mediated through a b3-AR.
DISCUSSION
Glucocorticoids have been investigated as potential mediators of
the process of cancer cachexia, since serum levels are elevated in
cachectic cancer patients compared with those without cachexia
(Knapp et al, 1991), and they have the potential for stimulation of
muscle proteolysis (Wing and Goldberg, 1993) and adipose tissue
lipolysis (Lacasa et al, 1988). However, this possibility has largely
been discounted, since wasting of body tissues was not prevented
by adrenalectomy in mice bearing the MG101 sarcoma (Svaninger
et al, 1987), while the glucocorticoid receptor antagonist RU38486
had no effect on the development of cachexia in rats bearing the
Yoshida AH-130 hepatoma (Llovera et al, 1996). It is not clear why
cachexia in these two models should be independent of
glucocorticoids, since in mice bearing the MAC16 tumour serum
levels of cortisol increased with increasing weight loss, and the
development of cachexia was attenuated by the glucocorticoid
receptor antagonist RU38486, with a concomitant reduction in
ZAG expression in adipose tissue. This suggests that elevation of
glucocorticoid levels during the development of cachexia is
responsible for the increased ZAG expression in adipose tissue,
which in turn leads to an increased lipid mobilisation and
utilisation (Russell and Tisdale, 2002). That glucocorticoids are
able to enhance ZAG expression in vivo has been confirmed by the
systemic administration of dexamethasone, suggesting that the
increased ZAG expression seen in adipose tissue of mice bearing
the MAC16 tumour (Bing et al, 2004) is probably due to circulating
cortisol. The only other potential mediator of the increased ZAG
expression in cachexia is interferon-g (IFNg), which has been
shown to strongly upregulate expression in human epithelial cell
lines (Brysk et al, 1997), and has been suggested to be responsible
for the development of cachexia in the Lewis lung tumour model
(Matthys et al, 1991b). However, cachexia in mice bearing the
MAC16 tumour is not thought to be cytokine mediated (Mulligan
et al, 1992), and is not associated with the development of anorexia
seen in mice inoculated with CHO cells transfected with the IFNg
gene (Matthys et al, 1991a).
Dexamethasone has been shown to decrease the body weight of
rats, decrease the amount of adipose tissue and increase the
catecholamine-stimulated lipolysis (Pedersen et al, 2003). Expo-
sure of adipose tissue fragments to dexamethasone has been shown
to lead to enhanced lipolytic and cyclic AMP responses to
isoprotorenol (Lacasa et al, 1988). The permissive effect of the
steroid was prevented by the glucocorticoid receptor antagonist
RU38486. The current study shows that dexamethasone directly
stimulated lipolysis in 3T3-L1 adipocytes, and that was associated
with an increased ZAG expression in cells and medium. The
lipolytic effect of ZAG was attenuated by RU38486, as was ZAG
expression. This suggests that the permissive effect of glucocorti-
coids towards lipolysis may result from an increase in ZAG
expression. Dexamethasone has been shown to stimulate adenylate
cyclase catalytic activity and response to GTP in fat cell
membranes (Lacasa et al, 1988). Zinc-a2-glycoprotein has also
been shown to cause a three-fold increase in lipolytic response to
isoprenaline, arising from changes in GTP-binding proteins (G-
proteins), with an increased expression of Gas and a decreased
expression of Gai in adipose tissue (Islam-Ali et al, 2001).
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Figure 4 Effect of various treatments on lipolysis in 3T3-L1 adipocytes, determined by the release of glycerol over a 24-h period. 3T3-L1 cells were
treated with isoprenaline (10mM), ZAG and LMF (0.57mM), dexamethasone alone (1.68mM) or combined with RU38486 (10mM), anti-mouse ZAG antibody
(1mgml
 1), EPA (50mM) or SR59230A (10mM) and the various inhibitors alone in a total volume of 2ml. The inhibitors were added 2h prior to the agonists.
Glycerol release was determined by an enzymatic/spectrascopic method as described (Wieland, 1974). The values shown are for n¼6. Differences from
control are indicated as c, Po0.001, while differences from dexamethasone alone are indicated as e, Po0.01.
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Figure 5 (A) Western blot of ZAG expression in 3T3-L1 adipocytes
from cells treated with PBS (lanes 1–3), dexamethasone
(1.68mM)þRU38486 (lanes 4–6), dexamethasone (1.68mM) (lanes 7–9)
or RU38486 (10mM) (lanes 10–12) for 24h. RU38486 was added 2h prior
to dexamethasone. Adipocytes were washed three times in PBS to remove
traces of media prior to homogenisation. n¼6. (B) Actin loading control
for the blot shown in (A). (C) Western blot of ZAG expression in media
from 3T3-L1 adipocytes treated with PBS (lanes 1 and 2), dexamethasone
(1.68mM) (lanes 3 and 4), dexamethasone (1.68mM)þRU38486 (10mM)
(lanes 5 and 6) or RU38486 (10mM) (lanes 7 and 8) for 24h. RU38486 was
added 2h prior to dexamethasone. n¼6. (C, D) Actin loading control for
the blot shown in (C).
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sThe mechanism by which glucocorticoids stimulate ZAG
expression appears complex, since expression was attenuated by
both a b3-AR antagonist and anti-ZAG antibody, as well as the
glucocorticoid receptor antagonist RU38486. This suggests that
dexamethasone induces ZAG initially through the glucocorticoid
receptor, and the ZAG moves into the medium and stimulates
further ZAG production via a b3-AR. Certainly the b3-AR agonist,
BRL37344 has been shown to increase ZAG mRNA levels in 3T3-L1
adipocytes (Bing et al, 2004). Glucocorticoids have a complex
effect on b3-AR expression in brown adipocytes (Bakopanos and
Silva, 2002). They rapidly and directly inhibit transcription, but
they also induce a rapidly turned-over protein that stimulates gene
transcription. It is therefore possible that glucocorticoids induce
b3-AR expression in 3T3-L1 adipocytes, amplifying the induction
of ZAG expression. Zinc-a2-glycoprotein itself has been shown to
induce ZAG expression in 3T3-L1 adipocytes, and this effect is
attenuated by anti-ZAG antibody and SR59230A, confirming that it
is mediated through a b3-AR, as for dexamethasone. Even though
human ZAG was used in these experiments it was capable of
inducing murine ZAG, suggesting that the mechanism of regula-
tion in the two species is probably identical. The mechanism by
which stimulation of b3-AR leads to an increased ZAG expression
is not known. The ability of ZAG to induce its own expression in
adipocytes would explain why the effect on lipolysis in vivo is
much greater than expected from the in vitro lipolytic effect
(Russell et al, 2004). It would also explain why relatively small
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12 34 5 6 7 8 9 1 0 1 1 12
123456789 1 0 1 1 1 2
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Figure 6 Expression of ZAG in cells (A) and medium (C) of 3T3-L1 adipocytes treated with PBS (lanes 1 and 2), SR59230A (10mM) (lanes 3 and 4)
(lanes 5 and 6 in (C)), dexamethasone (1.68mM) (lanes 5 and 6) (lanes 3 and 4 in (C)), dexamethasone (1.68mM)þSR59230A (10mM) (lanes 7 and 8),
dexamethasone (1.68mM)þanti-ZAG antibody (1mgml
 1) (lanes 9 and 10) and anti-ZAG antibody (1mgml
 1) (lanes 11 and 12) for 24h as determined by
Western blotting. The inhibitors were added 2h prior to the agonists. The actin loading controls are shown in (B) and (D).
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Figure 7 (A) Effect of ZAG on expression of ZAG in 3T3-L1 adipocytes
and in medium (C) treated with PBS (lanes 1–3 in (A) and lanes 1 and 2 in
(C)), ZAG (0.57mM) (lanes 4–6 in (A) and lanes 3 and 4 in (C)) and ZAG
(0.57mM)þanti-ZAG antibody (1mgml
 1) (lanes 7–9 in (A) and lanes 5
and 6 in (C)) for 24h. The antibody was added 2h prior to ZAG. The
adipocytes were washed three times with PBS prior to homogenisation to
remove traces of extracellular ZAG. n¼6. The actin loading controls are
shown in (B) and (D).
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Figure 8 (A) Effect of ZAG on expression of ZAG in 3T3-L1 adipocytes
and in medium (C) treated with PBS (lanes 1–3 in (A) and 1 and 2 in (C)),
ZAG (0.57mM) (lanes 4–6 in (A) and 3 and 4 in (C)) and ZAG
(0.57mM)þSR59230A (10mM) (lanes 7–9 in (A) and 5 and 6 in (C)) for
24h. SR59230A was added 2h prior to ZAG. The adipocytes were
washed three times in PBS prior to homogenisation to remove traces of
extracellular ZAG. The actin loading controls are shown in (B) and (D).
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schanges in plasma ZAG may have profound effects on lipid
mobilisation. These results suggest that induction of ZAG expres-
sion may play an important role in the action of glucocorticoids.
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